Deferoxamine mesylate (Ba 33112)

Catalog No.S5742 Synonyms: Desferrioxamine B, DFOM, NSC 644468

For research use only.

Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.

Deferoxamine mesylate (Ba 33112) Chemical Structure

CAS No. 138-14-7

Selleck's Deferoxamine mesylate (Ba 33112) has been cited by 29 publications

Purity & Quality Control

Choose Selective Ferroptosis Inhibitors

Biological Activity

Description Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.
Targets
HIF-1α [1]
()
Beta Amyloid [1]
()
Ferroptosis [2]
()
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-MC M2TrOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUnrbGZVPzJiaILz NXGybphuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU2FIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1NjVzIN88UU4> NVLnW25WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NFI3ODNpPkG3OlAzPjB|PD;hQi=>
SK-N-MC MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVi3NkBpenN? MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tUWMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWg{txONg>? NHTrOYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[wNVU4Pyd-MUm2NFE2Pzd:L3G+
SK-N-MC NUH4cJpNSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MY[3NkBpenN? M1zVb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{4{PSEQvF2u M4TBVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkG2OVYzLz5zOUKxOlU3OjxxYU6=
A549 MkP4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXHUb4tSPzJiaILz NF;CR2tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBifCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA4NjVizszNMi=> NHHyNIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2NVQ6QSd-MkK4OlE1QTl:L3G+
SK-N-MC NWHoRXNoSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NUPm[2ZDQTZiaILz M1LPNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gPE42QCEQvF2u MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzB4NEC2PUc,OTdyNkSwOlk9N2F-
MDCK MY\Uc5hq[2m2eTDhd5NigQ>? MmLWWI95cWOrdImgbY4hVUSFSzDj[YxteyCkeTDNWHQhdWW2aH;kMEBKSzVyIE2gPU41QSEQvF2u MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNEG2O|IoRjJyMESxOlczRC:jPh?=
SK-N-MC NWXDfGpnS3m2b4TvfIlkcXS7IHHzd4F6 MkLLO|IhcHK| M2HzZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vTVOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDlwOEmg{txONg>? NX[3UGdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFM4PjhpPkKwN|A{PzZ6PD;hQi=>
SK-N-MC MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUK3NkBpenN? MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDheEBpfW2jbjDTT{1PNU2FIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOCEQvF2u MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh4MUS5PUc,OjJ6NkG0PVk9N2F-
DMS53 M1HoXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1jGcVczKGi{cx?= MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDheEBpfW2jbjDEUXM2OyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVAh|ryPLh?= MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NkG0PVkoRjJ{OE[xOFk6RC:jPh?=
SK-MN-C M4LPXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV3OMWMh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTJwMEWg{txONg>? NH;t[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG1PVkzOid-MUixOVk6OjJ:L3G+
SK-N-MC MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NIjuZlk4OiCqcoO= NYPKdXE6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU2FIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyOi53IN88UU4> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh3OEGwNUc,OjJ6NUixNFE9N2F-
SK-N-MC NV3y[YtmSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= Mk\2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3OMW1EKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF2LkKyJO69VS5? MnntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7NkOzO|IoRjF5OU[zN|czRC:jPh?=
SK-N-MC NWfLWYFwXG:6aXPpeJkh[XO|YYm= MX;Uc5hq[2m2eTDpckBpfW2jbjDTT{1PNU2FIHPlcIx{KGK7IF3UWEBu\XSqb3SsJGlEPTBiPTCxOk4xPCEQvF2u MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB2MU[3Nkc,OjByNEG2O|I9N2F-
SK-N-MC MlrnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVXIeJU2PzJiaILz M1rKSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVYvQDFizszNMi=> M3jBRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OESxOVE1Lz5{OEi0NVUyPDxxYU6=
SK-N-MC NYfiTFE{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGPWZ3Y4OiCqcoO= M2H3O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNVcvODdizszNMi=> NVvKb5N3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwOVU6PTBpPkKxNFU2QTVyPD;hQi=>
SK-N-MC NH;QPYhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{C4OFczKGi{cx?= Mkf4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3OMW1EKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCxO{4xPyEQvF2u NHHLUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG3NlMyOSd-MkKxO|I{OTF:L3G+
U2OS M{LJRmZ2dmO2aX;uJIF{e2G7 M{XzeFMxKG2rboO= NEPpZ4JC[3SrdnH0bY9vKG:oIHj1cYFvKEiLRkHhcJBp[SCneIDy[ZN{\WRiaX6gSGZZNWmwZIXj[YQhcHWvYX6gWVJQWyClZXzsd{BqdmO3YnH0[YQh\m:{IEOwJI1qdnNicILpc5IhfG9iRF\YMYlv\HWldHnvckBu\WG|dYLl[EBi\nSncjDveoVzdmmpaISgbY5kfWKjdHnvckBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCxO{45KM7:TT6= NH:3N3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG3NlcxPCd-MkKxO|I4ODR:L3G+
HL60 M3y3WGN6fG:2b4jpZ4l1gSCjc4PhfS=> M1vl[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[nliYXzhcYFzKGKudXWgZZN{[XluIFfJOVAhRSBzOD60JO69VS5? MlTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[xPFUoRjJ|Mk[2NVg2RC:jPh?=
SK-N-MC MnLVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NF\QVmM4OiCqcoO= NFG5[HhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uVUNiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHH0JFM4KGSnZ1OgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjFwNkOg{txONg>? NXnZWIpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVI6PDhpPkKzN|EzQTR6PD;hQi=>
SK-N-MC NIixWGpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MkjMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3OMW1EKGOnbHzzMEBKSzVyIE2gNlIh|ryPLh?= M{\oNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkCxOVc4Lz5zOU[wNVU4PzxxYU6=
SK-N-MC NX3RVYtGSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NITyd3M4OiCqcoO= M{XOcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1OSyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNlIvPyEQvF2u NWDDdIhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OFYyOThpPkKxPFQ3OTF6PD;hQi=>
SK-N-MC MUXDfZRwfG:6aXPpeJkh[XO|YYm= MWm3NkBpenN? MUPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNU2FIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{Mj63JO69VS5? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ5NkKwPUc,OjN{N{[yNFk9N2F-
K562 M{TUVmN6fG:2b4jpZ4l1gSCjc4PhfS=> M{XIfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMtKEeLNUCgQUA{Oy5zIN88UU4> MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[xPFUoRjJ|Mk[2NVg2RC:jPh?=
HT29 M{fidGN6fG:2b4jpZ4l1gSCjc4PhfS=> M3\OW|czKGi{cx?= NYH2S5ZtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFR{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOzZwMTFOwG0v M2TyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{S1OlExLz5zOEO0OVYyODxxYU6=
HT-29 M{\QU2NmdGxiY4njcIUh[XO|YYm= M3u3dVExKHWP NGn5OnEzPCCqcoO= MlvNR4VtdCCleXPs[UBienKnc4SgbY4hdm:lb3Thfo9t\SCycnX0doVifGWmIHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDNJJBp[XOnIHH0JFExKHWPIHHmeIVzKDJ2IHjydy=> NHLhc3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO1N|E2Oid-MkCzOVMyPTJ:L3G+
HT-29 MUTD[YxtKGO7Y3zlJIF{e2G7 M2jmdlUhfU1? NXW1O|ZuOjRiaILz NX3jSXJOS2WubDDjfYNt\SCjcoLld5QhcW5ibn;jc4Rigm:uZTDwdoV1emWjdHXkJIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBOKHCqYYPlJIF1KDVidV2gZYZ1\XJiMkSgbJJ{ M{ntWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{WzNVUzLz5{MEO1N|E2OjxxYU6=
HCT116 NHK3c4lHfW6ldHnvckBie3OjeR?= MmrlNlQhcHK| MlnOVIhwfG:leYTveI95cWOrdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUheDV|IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIZwdGyxd3XkJIJ6KGyrZ3j0JIlzemGmaXH0bY9vKG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBOXFNiYYPzZZkhcW5icILld4Vv[2Vib3[gRWxCKGGwZDDG[WNtOw>? NYjicGpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzdpPkK0PVAxQDN5PD;hQi=>
HeLa M33ROWJi[3Sncnnvd5RifGmlIHHzd4F6 NWm1SXU5RjFyMDD1US=> Mn7SNUBpeg>? MXPCZYN1\XKrb4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KEOqbHHtfYRq[SC2cnHjbI9u[XSrczDz[ZJwfmG{IFyyJIlv\mWldHXkJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iY3;tdI92dmRidILlZZRm\CCjdDC+NVAxKHWPIH\vdkAyKGi{IIDybY9zKGmwZnXjeIlwdiCvZXHzeZJm\CB{NDDodpMheG:|dDDpcoZm[3Srb36gZpkhdWmlcn;zZ49xgQ>? NXPteFYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlc6OzdpPkK1NFI4QTN5PD;hQi=>
SK-N-BE(2)-M17 NYfXXZJUS3m2b4Dyc5Rm[3Srb36gZZN{[Xl? M2XDVlEhdU1? NYXT[lI6OiCqcoO= M4H4T2N6fG:ycn;0[YN1cW:wIHHnZYlve3RiUGGtbY5lfWOnZDDj[YxtKGSnYYToJIlvKGi3bXHuJHNMNU5vQlWoNkkuVTF5IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHH0JFEhdU1icILleJJm[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhOSCvTTDQVUBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjCyOEBpenNiYomgUGRJKGG|c3H5 NYrpN|dPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFU6OTVpPkK4Nlg2QTF3PD;hQi=>
SK-N-BE(2)-M17 M3jNRWN6fG:ycn;0[YN1cW:wIHHzd4F6 NIXyS4YyKG2P M4XBVlIhcHK| MnHIR5l1d3C{b4TlZ5Rqd25iYXfhbY5{fCCKMl:yMYlv\HWlZXSgZ4VtdCCmZXH0bEBqdiCqdX3hckBUUy2QLVLFLFIqNU1zNzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBk\WyuII\pZYJqdGm2eTDheEAyKG2PIIDy[ZRz\WG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDFibV2gTFJQOiCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAzPCCqcoOgZpkhVESKIHHzd4F6 NEDzcGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4OVkyPSd-MkiyPFU6OTV:L3G+
SK-N-BE(2)-M17 NIm1SI1EgXSxcILveIVkfGmxbjDhd5NigQ>? MXqxJI1O MXyyJIhzew>? MnvDR5l1d3C{b4TlZ5Rqd25iYXfhbY5{fCCSUT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hcHWvYX6gV2suVi2ERTiyLU1OOTdiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYYSgNUBuVSCycnX0doVifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUAyKG2PIGDRJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYm= NFHlPGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4OVkyPSd-MkiyPFU6OTV:L3G+
SK-N-BE(2)-M17 NHW3V5pEgXSxcILveIVkfGmxbjDhd5NigQ>? MV:xJI1O Mnr0NkBpenN? NV;JO4VvS3m2b4Dyc5Rm[3Srb36gZYdicW6|dDDINm8zNWmwZIXj[YQh[2WubDDk[YF1cCCrbjDoeY1idiCVSz3OMWJGMDJrLV2xO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBifCBzIH3NJJBz\XS{ZXH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IEGgcW0hUDKRMjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7 MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6NUmxOUc,Ojh{OEW5NVU9N2F-
DAOY NHvocHJyUFSVIHHzd4F6 M4G1TpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NXnJb4kzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MWPxTHRUKGG|c3H5 MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NUGwT2FKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M3naPZFJXFNiYYPzZZk> NVjFR2E4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 MmrOdWhVWyCjc4PhfS=> NVjSToJieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NVnzcHI4eUiWUzDhd5NigQ>? NF;DeFRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NUDCPVJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(152.25 mM)


* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 656.79
Formula

C26H52N6O11S

CAS No. 138-14-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Deferoxamine mesylate (Ba 33112) | Deferoxamine mesylate (Ba 33112) supplier | purchase Deferoxamine mesylate (Ba 33112) | Deferoxamine mesylate (Ba 33112) cost | Deferoxamine mesylate (Ba 33112) manufacturer | order Deferoxamine mesylate (Ba 33112) | Deferoxamine mesylate (Ba 33112) distributor